ReviewCurrent pharmaceutical design2025
A Review on Synthetic PLGA Polymer Incorporated with Phytocompounds: Elucidating the Molecular Cascades for Osteoporosis Treatment.
Review in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis, a skeletal disorder marked by the disruption and degeneration of bone tissues, undermines the structural integrity of bones. Globally, one in three women and one in five men face osteoporotic fractures as a result, and the expenditure on treating osteoporotic fractures is projected to surpass $25 billion by 2025. In addition to conventional medications such as monoclonal antibodies and hormonal therapies, research endeavors into bone tissue engineering due to the adverse effects associated with the prolonged use of pharmaceutical medications have spurred researchers to explore natural therapeutic compounds as a potentially safer and efficacious approach to treat osteoporosis. PLGA (Poly (lactic-co-glycolic acid)) is a copolymer that has garnered attention as a foundational material in biomedical applications due to its biocompatibility, its capacity to modify surface properties, and its ability to enhance interactions with biological materials. When combined with phytocompounds, PLGA has been reported to improve stability and efficacy in treating osteoporotic disorders. Various classes of bio-active phyto-compounds, including terpenoids, phenolic acids, alkaloids, and other nitrogen-containing metabolites, are recognized for their ability to stimulate osteogenic activities in osteoporotic conditions. They exert their effects by modulating signaling cascades in conjunction with bone growth factors. In recent years, natural polymers derived from bio-active compounds have garnered growing interest owing to their wide-ranging applications in biomedicine. This review provides comprehensive insights into the role of phytocompounds in targeting genes involved in the bone regeneration process. Additionally, it highlights the potential of the synthetic polymer PLGA in improving treatments for osteoporotic conditions.
Indexed as
Identifiers
40207819What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.